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Background: Virus-host interactions result in altered gene expression profiles in host cell nuclei and enable virus
particle production, thus obligatorily involving changes in their epigenomes. Neither such epigenome changes nor
their response to antiviral treatment have been extensively studied to date, although viral infections are known to
contribute to the long-term development of severe secondary diseases, for example, hepatocellular carcinoma. This
may be causally linked to virus-induced persistent plastic chromatin deformations.
Results: We studied whether impaired hepatitis B virus (HBV) replication can lead to the restitution of epigenome
signatures hypothesizing that hepatocytes alternatively could adopt a ‘memory’ state of the infection; that is, the
chromatin could persist in a HBV-induced configuration potentially inheritable between dividing hepatocytes. We
therefore determined epigenomic signatures and gene expression changes altered by HBV and the effects of
suppressed HBV replication in nontransformed hepatocytes of newborn mice. Further we investigated differential
histone acetyltransferase and histone deacetylase activities in HBV-negative and HBVpositive hepatocytes, as well as
the effects of HBV suppression on gene expression and the chromatin landscape. We show that the expression of
several genes and the chromatin landscape become altered upon HBV infection, including global hypoacetylation
of H2A.Z and H3K9. Reporter assays monitoring the activities of histone acetyltransferases or histone deacetylases,
respectively, suggest that hypoacetylation most probably depends on elevated sirtuin deacetylase activity, but not
on class I/II histone deacetylases. Using Micrococcus nuclease to study the chromatin accessibility in met murine-D3
and hepatitis B virus met murine hepatocytes, we demonstrate that the observed differences in H2A.Z/H3K9
acetylation lead to global chromatin structure changes. At all selected sites examined by chromatin
immunoprecipitation and quantitative real-time PCR, these effects can be partly restituted via the nucleoside analog
reverse transcriptase inhibitor 3TC or using anti-HBV microRNA-like molecules.
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Conclusions: Increased sirtuin activity might lead to global histone hypoacetylation signatures, which could
contribute to the HBV-induced pathomechanism in nontransformed hepatocytes. Using several techniques to
suppress HBV replication, we observed restituted gene expression and chromatin signature patterns reminiscent of
noninfected hepatocytes. Importantly, ectopic expression of antiviral short-hairpin RNA, but not microRNA-like
molecules, provoked intolerable off-target effects on the gene expression level.
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To enhance virus particle production, virus-host interac-
tions lead to manipulation of gene expression patterns in
the infected cells, which necessarily involve changes in the
epigenome. Neither such virus-induced host epigenome
changes nor the response of these changes to therapies
have extensively been studied to date, although it seems
obvious that over the long term, several viral infections
can contribute to the development of severe secondary
diseases, which may be causally linked with persistent
plastic chromatin deformations. For example, enforcement
of hepatitis B virus (HBV) replication over long periods
can eventually contribute to the development of chronic
hepatitis B, liver cirrhosis and hepatocellular carcinoma
(HCC). Globally, more than 350 million people are chron-
ically infected with HBV; thus chronic hepatitis B belongs
to the list of most common infectious diseases [1]. The
most common mode of HBV transmission is vertically
from mother to child with up to 90% of the neonates born
to hepatitis B surface antigen (HBsAg)-positive mothers
running the risk of becoming infected [2]. Chronic disease
occurs mainly when the infection happens early in life
during childhood. Adults become chronically diseased in
only 5 to 10% of cases, whereas chronification rates can be
higher than 90% when infants become infected in the first
six months of life. Possible sequels of chronic hepatitis B
are liver cirrhosis and cancer. In fact, chronic hepatitis B
correlates with a 37-fold elevated probability of developing
HCC [3]. However, the molecular reasons for these age-
related differences in chronification remain unknown to
date. It is also not known whether antiviral interventions
lead to a restitution of epigenome patterns in host cells
manipulated by HBV. Alternatively, one could hypothesize
that hepatocyte nuclei adopt a ‘memory’ state of the HBV
infection even if viral replication is suppressed; that is, the
chromatin might persist in an HBV-manipulated configur-
ation, which could be inheritable between dividing hepato-
cytes and could contribute to elevated secondary disease
susceptibility.
Apart from the outstanding clinical relevance of eluci-
dating the early pathomechanisms of HBV infection, this
pathogen can serve as minimalistic model for virus-host
interactions in general. The small 3.0 to 3.2 kbp HBV
genome encodes only four genes, giving rise to sevenproteins: HBVgp1 (polymerase), HBVgp2 (large S pro-
tein/middle S protein/S protein), HBVgp3 (X protein)
and HBVgp4 (precore/core protein). The genome con-
sists of partially double-stranded DNA, which is repli-
cated via an RNA intermediate by reverse transcription
through the HBV polymerase. Chronic HBV infections
are accompanied by the persistence of the viral genomic
covalently closed circular DNA (cccDNA) as stable epi-
somes within hepatocyte nuclei, serving as a template
for viral protein expression [4]. It is assumed that the X
protein (HBx) acts as a transregulator and contributes to
the malignant transformation of hepatocytes, and evi-
dence increases that hepatocyte transregulation involves
chromatin-modifying mechanisms, which act on the epi-
genomes of both the cccDNA and the host cells. HBx
enrichment apparently leads to elevated DNA methyl-
transferase (DNMTs) levels [4-6]. In hepatocellular car-
cinoma cells transfected with wild-type HBV genomes,
the histone acetyltransferase (HAT) p300 becomes re-
cruited to the cccDNA. Concomitantly, levels of acety-
lated histones H3 and H4 (H3ac/H4ac) associated with
the cccDNA increase and viral replication is enhanced. In
contrast, p300-binding and H3ac/H4ac are reduced in
hepatoma cells expressing a nonfunctional HBx [5]. More-
over histone deacetylases (HDACs) become recruited to
the cccDNA via HBx, suggesting that this protein is crit-
ical for chromatin structure regulation of the cccDNA [4].
Although a few available studies underline the relevance
of chromatin-modifying mechanisms for episomal stability
of the cccDNA, HBV replication, viral gene expression and
host cell reprogramming, most of that data resulted from
studies in HCC cell lines or biopsies. In those samples, early
epigenetic trans-acting decisions are indistinguishable from
later events, and most models do not focus on the in-
creased chronification susceptibility in infected infants. As
a consequence, spatiotemporal dynamics of regulatory net-
works at the onset of chronic hepatitis B infection are not
yet understood, but might be relevant for therapy decisions
and antiviral drug development. To contribute, we com-
pared the abundance of 80 mRNAs corresponding to genes
relevant for HCC development in HBV-negative and HBV-
positive nontransformed hepatocytes, which derived from
newborn mice. We analyzed underlying chromatin signa-
tures and investigated the response of hepatocytes upon
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Results
Accumulation patterns of several messenger RNAs differ
between noncancer and hepatocellular carcinoma
hepatocytes upon chronic hepatitis B virus infection
It is clear that the time-displaced development of hepato-
cellular carcinoma can be an endpoint of chronic hepatitis
B infection, and numerous piloting studies in the field have
already compared gene expression profile differences in cell
line models such as HepG2 hepatoma cells and HBV-
positive HepG2.2.15 cells. However, the differences be-
tween chronic nontransformed HBV-positive hepatocytes
and transformed HBV-positive hepatocytes have not been
extensively studied so far. To confirm the importance of
these differences, we studied the relative differential accu-
mulation of numerous messenger RNAs (mRNAs) in
HBV-positive murine liver biopsies (1.2.32 (Tg [HBV 1.3
genome] Chi32) lineage), which corresponded to more
than 80 genes associated with liver cancer development
and housekeeping genes by quantitative real-time polymer-
ase chain reaction (qPCR) (Table 1; [see Additional file 1:
Figure S1A]). The biopsies were obtained from 24-month-
old mice (n = 5), which did not develop HCC or which
developed HCC (N = 5). Our analyses showed - depending
on whether HSP90AB1 and ACTB were used for norma-
lization or, alternatively, a combination of HSP90AB1,
ACTB and GAPDH was used - that approximately 11 to
24% of the examined mRNAs were differentially deregu-
lated. This observation highlights why it is reasonable to
focus on nontransformed models of HBV infection in
order to elucidate mechanisms in the hepatocellular regu-
lome, which become modulated by HBV and potentially
contribute to the development of HCC.
Selective gene deregulation events are associated with
chronic hepatitis B virus infection in nontransformed
hepatocytes
To study gene expression changes and underlying epige-
nome signatures in nontransformed hepatocytes upon
chronic HBV infection, which might possibly be relevant
for HCC development, we made use of the immortalized,
nontransformed murine hepatocyte cell lines met murine
hepatocytes (MMH)-D3 (HBV-negative) and hepatitis B
virus met murine hepatocytes (HBV-Met) (HBV-positive),
which were derived from newborn mice [7,8]. We ana-
lyzed the expression of over 80 liver cancer-related genes
using qPCR arrays on reverse-transcribed RNA isolated
from five biological replicates of MMH-D3 and six bio-
logical replicates of HBV-Met cell lines. Whereas most
mRNAs did not exhibit significant differences in their
relative abundance, CDH13 (B03) was significantly up-
regulated in HBV-Met. In contrast, CDKN2A (B06), WT1(G10) and DLC1 (B11) were downregulated in HBV-Met
when compared to MMH-D3 (Table 1; Figure 1A; [see
Additional file 1: Figure S1B]) (all P <0.05). Several other
mRNAs showed a tendency to be up- or downregulated,
whereas most of these fold-changes did not reach signifi-
cance (P ≥0.05). KDR (D07), IGFBP1 (D03) and IGFBP3
(D04) seemed to be slightly upregulated. In contrast,
IGF2 (D02), CDH1 (B02), fragile histidine triad protein/
FHIT (C06), gluthatione S-transferase pi 1/GSTP1 (C10),
cyclin-dependent kinase inhibitor 1A/CDKN1A (B04) and
signal transducer and activator of transcription 3/STAT3
(F11) seemed to be slightly downregulated. Also beta-
glucuronidase/GUSB (H01), which was referred to as the
housekeeping gene in the array, was significantly downreg-
ulated. We therefore decided not to use GUSB for
normalization. Remarkably, we recognized that more
genes became downregulated than upregulated. We were
then interested in whether our observations made on the
MMH-D3 and HBV-Met cells also hold for infected
humans. To evaluate, we compared the expression of se-
lected human genes between three HBV-negative and
three HBV-positive age- and gender-matched adolescents
(non-HCC) [see Additional file 1: Figure S1C] and gath-
ered information from the literature (Table 1). The HBV-
negative control group exhibited elevated transaminases,
justifying diagnostic needle aspiration liver biopsies. Even-
tually, no evidence for liver diseases was found in any of
the cases. In agreement with our observations in the
MMH-D3/HBV-Met mouse cell system, CDH13 mRNA
was significantly enriched in HBV-positive specimens, but
IGFBP3 also seemed to be slightly upregulated. Concomi-
tantly, DLC1 and CDKN2A mRNAs were significantly
downregulated. No significant difference was found for
the accumulation of IGFBP1 and KDR mRNAs between
the HBV-positive and HBV-negative juvenile liver samples,
whereas WT1 was highly enriched in the HBV-positive
specimens. Remarkably, this was the only observed stark
contrast between cultivated nontransformed murine hepa-
tocytes and human samples.
Antiviral treatment entails partial restitution of met
murine hepatocytes-D3-like expression patterns, but also
causes severe side effects when short-hairpin RNA is used
for hepatitis B virus suppression
To verify the functional connection between the pres-
ence of the HBV genome and the observed differences
in gene expression patterns, we suppressed HBV replica-
tion in HBV-Met using different approaches. Thereafter,
we compared the expression of selected genes in these
cells with untreated HBV-Met (Figure 1A,B,C,E-G).
With respect to our initial experiment, these genes were
selected from three groups. Group 1 was composed of
the ten most upregulated genes in the HBV-Met, group
2 of the ten most downregulated genes, and group 3 was
Table 1 Overview of experimental and literature evidence for several differentially expressed genes and CpG signaling in mouse and humans












CDH13 Regulation of cell-
cell contacts
up (P <0.01) no Pubmed hit; upregulation observed in
chronic HBV infection (n = 3) versus
HBV-negative liver biopsies (n = 3),
P <0.05









no Pubmed hit; no significant change
observed in chronic HBV infection (n = 3)
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normal5 Na no Pubmed
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1 Yu, BMC Cancer. 2002 PMID: 12433278 6 Li, Clin Cancer
Res. 2004 PMID: 15569978 7 Kaneto, Gut 2001 PMID:
11171828 8 Shim, Cancer Lett 2003 PMID: 12565176
WT1 Tumor suppressor down
(P <0.01)
down early: normal hepatocytes expressing
HBx5/HBV-positive biopsies5 versus ‘
significant upregulation observed in chronic
HBV infection (n = 3) versus HBV-negative
liver biopsies (n = 3)’
up9,10,11 Na hyper5meC
(HCC)12,13
5 Wu, Oncogene. 2001 PMID: 11439330 9 Uesugi, J
Gastroenterol. 2013 PMID: 23142971 10 Perugorria, Cancer
Res. 2009 PMID: 19190340 11 Sera, Eur J Cancer 2008 PMID:
18255279 12 Yu, Cell Res. 2003 PMID: 14672555 13 Zhang,
Clin Cancer Res. 2007 PMID: 17289889
DLC1 Tumor suppressor down
(P <0.01)
significant upregulation observed
in chronic HBV infection
down14,15,16 Na elevated
5meC (HCC)15
14 Dong, Cancer Epidemiol. 2009 PMID: 19766077 15
Wong, Cancer Res. 2003 PMID: 14633684 16 Leung-Kuen,
PLoS One 2013 PMID: 23826380
Abbreviations: CDH13 cadherin 13, CDKN2A cyclin-dependent kinase inhibitor 2A, DLC1 deleted in liver cancer 1 IGF, insulin-like growth factor, IGFBP1/3














Figure 1 Gene expression analyses in hepatitis B virus met murine hepatocytes (HBV-Met) with suppressed hepatitis B virus (HBV)
replication versus untreated HBV-Met. A. Relative enrichment of mRNA in MMH-D3 versus HBV-Met. H02 to H05 were used for normalization.
B. 3TC-treated HBV-Met versus HBV-Met. C. HBV-Met treated with siRNA versus HBV-Met. D. pEPI-U6-shRNA and assessment of HBsAg. E. HBV-Met
treated with antiviral short-hairpin RNA (shRNA) versus HBV-Met. F. HBV-Met treated with nonesense shRNA versus HBV-Met. G. Signal subtraction
results from D and E. A-G. Statistical data are represented as boxplots displaying median fold-differences, interquartile range, and minimum/
maximum values. Gray-shaded: fold-change range between −2.0x/+2.0x. Green: Ten most upregulated genes; red: Ten most downregulated
genes. Cyan: 8 selected stably expressed genes. Fold-changes >1 indicate upregulation in HBV-Met versus MMH-D3; fold-changes <1 indicate
downregulation. **P ≤0.01; *0.01≤ P ≤0.05.
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Firstly, we treated HBV-Met with the nucleoside analog
reverse transcriptase inhibitor 2′,3′-dideoxy-3′-thiacyti-
dine (3TC/lamivudine) (Figure 1B), which is widely used
for chronic hepatitis B treatment. Whereas expression pat-
terns of most genes examined did not differ significantly
from HBV-Met, three of the genes upregulated in HBV-
Met versus MMH-D3 those that were downregulated in
the 3TC-treated HBV-Met (reelin/RELN/F03, KDR/D07,
and IGFBP1/D03). Remarkably, CDKN2A (B06) and CDH1
(B02) exhibited differential expression patterns reminiscent
of HBV-Met when compared with the HBV-negative
MMH-D3, whereby both genes were downregulated or si-
lenced in HBV-Met (Figure 1B). To complement this ex-
periment, we utilized RNA interference to target HBV
transcripts in HBV-Met, which in theory enables more spe-
cific suppression of HBV replication. Initially we selected
putative siRNA candidate sequences against sites encoded
within ORF P, ORF S or ORF X and a mock small interfer-
ing RNA (siRNA) without homology to human or HBV
transcripts (nonsense siRNA). These siRNAs were trans-
fected into HBV-Met prior to periodical quantification of
HBsAg in cell culture supernatants over 5 days. In HBV-
Met cells the most efficient siRNAs against ORF X tran-
scripts tested led to an approximately 80% reduction of
HBV replication as deduced by HBsAg measurements in
the supernatant. We purified RNA from these cells to per-
form qPCR arrays analyses as described. Expressionpatterns of several genes examined were reminiscent of
those obtained, when HBV-Met were compared with
MMH-D3 (Figure 1C). In detail KDR (D07), IGFBP3 (D04)
and protein tyrosine kinase 2/PTK2 (E10) were upregulated
after siRNA treatment, whereas CDH1 (B02), GUSB (H01)
and CDKN2A (B06) were downregulated. All group 3
genes remained stable. To study longer term effects, we
performed experiments using antiviral small RNA mole-
cules expressed from optimized pEPI-RNAi derivatives
[9,10]. We transfected different pEPI-U6-small hairpin
RNA (shRNA) constructs into HBV-Met. HBV replication
in HBV-Met was monitored after growth for 3 and
8 months, respectively, showing that HBV suppression was
efficient and stable (Figure 1D). Subsequently we analyzed
gene expression in HBV-Met 3 months after transfection
with pEPI-U6-shRNA-X1. Upon expression of the antiviral
shRNA dramatic expression changes for many of the genes
examined were observed (Figure 1E-G). Over 50% of the
examined genes appeared to be downregulated in shRNA-
treated HBV-Met, when compared to untreated controls.
These patterns differed starkly from MMH-D3. To test
whether the observed effects were target sequence-specific,
a nonesense shRNA expressing pEPI vector (Figure 1F) or
solely the pEPI-luciferase backbone was established in HBV-
Met cells [see Additional file 1: Figure S2]. These controls
revealed that the pEPI-luciferase vector alone caused at best
minor off-target effects, whereas interestingly, the expression
of nonsense-shRNA caused almost congruent gene expres-
sion patterns as described for the use of HBV-directed
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fold-changes caused by nonsense-shRNA from fold-changes
caused by HBV-directed shRNA, none of the genes investi-
gated showed significant differences, suggesting that almost
all observed gene expression changes were directly and
specifically induced by shRNA (Figure 1G). Only CDKN2A
(B06) expression appeared to be diminished in HBV-Met
when compared to shRNA-treated HBV-Met. These off-
target effects obviously induced by shRNA expression clearly
reduced the value of such experiments for the study of
HBV-induced changes in the transcriptome of host cells and
for clinical application. We therefore decided to camouflage
the antiviral target sequences as the cell’s own microRNA
(miRNA) in similar ways, as miRNA-30-like precursors have
been used for the study of gene function before [11] to cir-
cumvent a hypothetical cellular response mechanism. With
respect to miRBASE [12], we designed stem-loop hsa-
miRNA-like oligonucleotides and cloned them into the pEPI
vector system, giving rise to pEPI-U6-miR/pEPI-H1-
miRNA plasmids (Figure 2A, B).
To optimize the use of antiviral miR, we constructed al-
ternative pEPI-miRNA vectors using different miRNA tem-
plates, which were reportedly expressed in human liver
(Figure 2A) [12], in combination with either the human
H1 or U6 RNA polymerase III promoter. Furthermore we
made use of different antiviral target sequences to replace
mature 5p-miRNA sequences within the stem-loop precur-
sors (Figure 2B). After transfection into HBV-Met of
HBsAg quantities in the cell culture supernatant were
assessed over a period of 5 days (Figure 2C). We noted that
HBsAg concentrations were slightly lower using the H1
promoter construct. Also HBsAg suppression was slightly
more efficient, when a miRNA-26-like construct was used,
whereby miRNA-122-like and miRNA-30-like constructs
exhibited similar efficiency. Target sequence selection was
apparently more relevant for the HBV suppression potency
of miRs (target X1 >X2 > S). Eventually we selected a
pEPI-U6-miRNA-30-like clone targeting transcripts of
HBV ORF X/ORF P for further experiments. Following
transfection into HBV-Met, selection and growth over
3 months, we performed comparative gene expression
studies (Figure 2D). Strikingly, the pronounced off-target
effects on hepatocyte gene expression patterns seen in the
shRNA-treated HBV-Met were not observed after epi-
somal miRNA expression. Moreover, gene expression pat-
terns of several genes were reminiscent of the patterns
obtained when HBV-negative MMH-D3 were compared
with HBV-positive HBV-Met.
Reversible hepatitis B virus-induced hypoacetylation
shapes the epigenomic landscape in nontransformed
hepatocytes
Since chromatin, rather than naked DNA, is the substrate
for gene expression in the cell nucleus, the ability ofviruses to direct chromatin modifications is a prerequisite
for reprogramming the host cell transcription machinery
for virus particle production [13]. In this context, it is not-
able that acquired epigenetic abnormalities possess similar
relevance for malignant transformation of cells to muta-
tions in the genome [14]. Thus changes in the epigenomic
signature implemented by chronic viral infections might
harbor the risk of malignant transformation. We therefore
investigated whether epigenomic markers associated with
several sites within promoters of selected genes, such as
DNA cytosine methylation (5meC) or post-translational
modifications of histones (PTM), became differentially
manipulated by HBV. Using methylated DNA immuno-
precipitation (MeDIP) in combination with qPCR, we ana-
lyzed whether selected CpG-rich ‘island’ or ‘shore’ sites
localized within the promoters of several genes could be
pulled-down using 5meC specific antibodies (Figure 3).
These putative DNA methylation target sites were associ-
ated with selected genes differentially repressed in HBV-
Met (for example, CDKN2A, CDKN1A) or with genes
being previously described as hypermethylated in HCC
(for example, GSTP1 and CDH13) [15,16]. We were sur-
prised to some extent that we did not observe obvious dif-
ferences of 5meC enrichment, whereby most sites were
either hypomethylated or exhibited an intermediate level
of DNA methylation in both cell lines. As expected, the
control genes used were detected being either hypomethy-
lated (glyceraldehyde-3-phosphate dehydrogenase/GAPDH)
or hypermethylated (testis-specific histone 2B/TSH2B). We
speculated that previously reported DNA hypermethyla-
tion could be a false-positive artifact, which could result
from the enrichment of hydroxymethylated cytosines at
sites being investigated. Bisulfite-dependent methods are
known to be prone to false-positive detection of methyl-
ated cytosines in cases where the putative DNA demethyla-
tion intermediate 5-hydroxymethylcytosine (5hmeC) is
highly enriched [17]. To complement and to test whether
relevant 5hmeC levels were detectable, we applied 5hmeC-
specific antibodies for immunoprecipitation. Again, no ob-
vious differences were seen in HBV-Met versus MMH-D3
(Figure 3). With respect to a hydroxymethylated control
gene (splicing factor 1/SF1), we detected biologically rele-
vant enrichment of 5hmeC at several sites in the promoters
of CDKN2A, CDKN1A, GSTP1, CDH13 and myeloid cell
leukemia sequence 1/MCL1. Since no differential patterns
responsible for the transregulation of selected genes by
HBV were seen on the DNA methylation/hydroxymethyla-
tion levels, we went on to study putatively differential pat-
terns of histone modifications (Figure 4). Earlier studies
reported a linkage between HBV infection and HAT
(p300) or HDAC recruitment in hepatocytes. As an initial
approach we thus selected H2A.Zac as well as H3K9ac as
markers to study possible epigenome-wide differences in
nuclear extracts from HBV-Met and MMH-D3 cells by
Figure 2 (See legend on next page.)
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Figure 2 Suppression of hepatitis B virus (HBV) replication using microRNA (miRNA)-like molecules. A. Stem-loop structures of hsa-miRs
containing antiviral target sequences. B. HBV transcripts and corresponding target sequences on the covalently closed circular DNA (cccDNA).
C. Hepatitis B surface antigen (HBsAg) assessment upon hepatitis B virus met murine hepatocytes (HBV-Met) treatment with candidate miRs.
D. Gene expression analyses in HBV-Met treated with miRNA-30 L-X1 versus untreated HBV-Met. Statistics and coloring correspond to Figure 1A-G.
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that both H2A.Zac and H3K9ac were enriched in MMH-
D3 cells, when compared to HBV-Met cells. We assumed
that histone hypoacetylation could theoretically result from
either reduced histone acetyltransferase activity or from el-
evated histone deacetylase activity or from a combination
of all. We therefore performed various reporter assays to
get insight into differences in relevant chromatin modifying
activities in HBV-Met cells versus MMH-D3 cells. We
could not observe significant differences in the activities of
HATs (Figure 4B) or class I and II HDACs (Figure 4C) be-
tween both hepatocyte lines. Interestingly, we detected sig-
nificantly increased relative activity of the NAD+-dependent
HDAC class III enzymes (sirtuins) (Figure 4D). We were
next interested in whether one or several of the seven mur-
ine sirtuin genes present in the mouse genome were differ-
entially regulated between HBV-Met and MMH-D3 cells.
As a preliminary approach, we performed qPCR, measur-
ing the differential accumulation of SIRT1-7 mRNAs in
both cell lines. Notably we observed that the mRNAs of
SIRT1, SIRT2, SIRT4 and SIRT7 were slightly but signifi-
cantly (*0.01 ≤ P ≤ 0.05) elevated in HBV-Met cells when
compared with MMH-D3 cells, whereby SIRT3 and SIRT4
could not be detected in either cell line [see Additional
file 1: Figure S3]. In summary, both observations - the de-
creased presence of H2A.Zac and H3K9ac, as well as the
elevated relative sirtuin deacetylase activity in HBV-Met
hepatocytes - suggest that the observed hypoacetylation at
specific sites reflects a global, epigenome-wide effect.
Since histone acetylation is generally believed to be
associated with a decondensed chromatin structure, weFigure 3 Recovery of 5meC and 5hmeC at selected sites. MMH-D3 (‘A’
hepatocytes (HBV-Met) (‘B’ as part of the x-axis caption). Blue boxes: 5meC; red
interquartile range, and minimum/maximum values.hypothesized that - as a structural consequence of the
increased sirtuin deacetylase activity in HBV-Met cells -
global histone hypoacetylation could favor a condensed
chromatin structure, leading to reduced chromatin acces-
sibility in HBV-Met cells. Alternatively the observed his-
tone hypoacetylation could also be explained by reduced
nucleosome occupancy in the HBV-positive hepatocytes,
which would be reminiscent of the age-related thinning of
nucleosome occupancy in single-celled eukaryotes and
mammals [18]. In theory, such reduced nucleosome occu-
pancy could lead to enhanced accessibility of chromatin.
We therefore assessed the chromatin accessibility over
time using Micrococcus nuclease (MNase) assays. Using
microcapillary electrophoresis, we observed that the
enrichment of DNA bands corresponding to mono-, di-
and trinucleosomes was deferred in HBV-Met when com-
pared with MMH-D3 (Figure 4E, left). We further moni-
tored the intensity ratios between the undigested gDNA
and the DNA band, which corresponded to mononucleo-
somes (Figure 4E, right). These intensity ratios were sig-
nificantly lower at time points 1, 2, 4 and 8 minutes,
showing that chromatin purified from MMH-D3 cells was
more accessible for MNase when compared to HBV-Met
chromatin. These results provided strong evidence that
the detected histone hypoacetylation led to changes in the
global chromatin structure of HBV-Met cell nuclei.
In order to study the observed differences in the turn-
over of H2A.Zac and H3K9ac in more detail and to elu-
cidate the influence of HBV-suppressive interventions,
we went on to analyze histone PTM patterns by chroma-
tin immunoprecipitation (ChIP) and qPCR (Figure 4F).as part of the x-axis caption) versus hepatitis B virus met murine
boxes: 5hmeC. Data are presented as median fold-differences,
Figure 4 (See legend on next page.)
Jenke et al. Clinical Epigenetics 2014, 6:26 Page 9 of 15
http://www.clinicalepigeneticsjournal.com/content/6/1/26
(See figure on previous page.)
Figure 4 Comparative analyses of histone acetylation and chromatin structure in met murine hepatocytes (MMH)-D3 versus hepatitis B
virus met murine hepatocytes (HBV-Met) cells. A. Western blot analyses of H3K9ac (left) or H2A.Zac (right) enrichment in MMH-D3 and
HBV-Met cells. Beta-actin was used as loading control. B-D. Assays of histone acetyltransferase (HAT)/ histone deacetylase (HDAC) activities.
B. HAT activity ELISA using nuclear extracts from 10.000 of each of both cell lines MMH-D3 and HBV-Met. The dots and the trend line correspond
to the kit’s standards, whereas the boxplots (referring to the y-axis only) represent the results of several measurements (n =10 for each cell line)
using MMH-D3 or HBV-Met cells. C. Results of class I/II HDAC activity measurements over time using 10.000 cells from each of the two cell lines for
luminescence reporter assays. D. Results of class III HDAC activity (sirtuins) measurements over time using 20.000 cells from each of the two cell lines
for luminescence reporter assays. E. Results of MNase digests over time using isolated nuclei from 1x 106 cells per time point. F. Fold-change differences
of H2A.Zac/H3K9ac recovery at selected sites. HBV-Met versus MMH-D3 or HBV-Met with suppressed hepatitis B virus (HBV) replication. For each site
recovery from HBV-Met was used for normalization.
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eight genes as anchor points. Strikingly, at all sites exam-
ined, we discovered highly significant hypoacetylation of
H2A.Z and H3K9 in HBV-Met versus MMH-D3. To
analyze whether these acetylation pattern changes were
due to the presence or replication activity of HBV, we
made use of several suppression techniques as described
above. Importantly, upon impaired HBV replication,
these experiments showed that chromatin signatures
reminiscent of HBV-negative MMH-D3 were apparently
restituted with varying quality for both H2A.Zac and
H3K9ac. The best apparent quality was particularly
achieved when the anti-HBV miRNA-like molecules
mimicking hsa-miR30a were used. In contrast, the ex-
pression of a nonesense miRNA did not lead to changed
H2A.Zac and H3K9ac patterns that were distinguishable
from untreated HBV-Met.
Discussion
To study the mechanisms relevant for chronification of
hepatitis B with an emphasis on infantile HBV infections
and the possible later malignant transformation of hepa-
tocytes in the course of chronic HBV infection, it is rea-
sonable to utilize experimental nontransformed models
instead of hepatoblastoma cells, which already exhibit
carcinogenic modified profiles of their epigenomes and
transcriptomes. We therefore used the primary hepato-
cyte lines HBV-Met and MMH-D3. The latter derived
from primary hepatocytes of newborn transgenic mice
expressing the hepatocyte growth factor receptor/MET
proto-oncogene, which encodes the transmembrane re-
ceptor, whose extracellular domain was truncated. This
gave rise to apoptosis-resistant, immortalized but non-
transformed, well-differentiated hepatocytes [8]. Immor-
talized primary HBV-Met hepatocytes were cultured
from the newborn offspring of cyto-Met mice parental
for MMH-D3, which were bred with HBV-transgenic
mice. These mice replicated HBV from an integrated
transcriptional template encoding all full-length HBV
transcripts at a replication level comparable to patients
with chronic hepatitis B [7]. These characteristics of
both related hepatocyte lines made them a preferable
in vitro model for the intended studies.Focusing on genes potentially relevant for HCC develop-
ment we detected upregulation of CDH13, KDR, IGFBP1/
3 and downregulation of CDKN2A, WT1, DLC1 suggest-
ing that transregulation of these genes might play a role in
the early phase of malignant hepatocyte transformation.
Interestingly, CDH13 was earlier observed being silenced
in HCC, but overexpressed in intratumoral endothelial
cells. It was also noted that its overexpression could
stimulate proliferation and motility of endothelial cells
and was associated with vascular endothelial growth fac-
tor/VEGF-driven angiogenesis [19]. One VEGF-responsive
receptor is encoded by KDR. Elevated expression of KDR
was earlier assumed to be involved in the regulation of
VEGF-mediated HCC development and angiogenesis at
early and later stages of tumor development [20]. Our ob-
servation that CDH13, and possibly to some extent KDR,
was among the most prominently upregulated genes in
HBV-Met strengthens the hypothesis that VEGF-signaling
in addition to other growth factor-mediated pathways is
important in HBV-induced HCC development [21]. At
the same time elevated IGFBP3/1 levels as observed in
our study possibly indicate a continuance of a compet-
ing growth-limiting response at this precancer stage.
Apparently this response eventually diminishes, since
others consistently reported it to be repressed in HCC
[22,23]. Concomitantly, tumor suppressor genes such
as CDKN2A, WT1 and DLC1 became downregulated in
HBV-Met. Shutdown of these genes was earlier associ-
ated with HCC or with tumors of other entities [24-26],
but our findings highlight that targeted repression of
these anti-proliferative genes might be tightly entangled
with an early onset of malignancy. Notably, while we
obtained very similar mRNA accumulation profiles in
cultured murine hepatocytes and human liver samples for
almost all differentially regulated genes, the observed
deprivation of WT1 mRNA in HBV-Met cells was in stark
contrast to its significant enrichment in HBV-positive
human liver samples. This accumulation in human non-
HCC samples was reminiscent of several reported cases,
where WT1 mRNA was enriched in hepatocellular cell
carcinoma [27-29]. In summary, a common set of genes
seems to be deregulated in several HBV-positive cell
models including HBV-Met, but some remarkable
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the chimeric nature of the HBV-Met model, which
contains the human HBV genome integrated into a
murine hepatocyte genome. Therefore, the relevance
of several observations still has to be judged with care
and will need further examination in future.
From a clinical perspective, however, it is desirable to
know whether these changes are reversible upon HBV
suppression. We therefore used several techniques to in-
vestigate whether knockdown of HBV replication could
restore MMH-D3-like gene expression patterns. It seemed
reasonable to make use of the nucleoside analog reverse
transcriptase inhibitor 3TC because the HBV-Met cells
replicate HBV from the integrated greater-than-genome-
length HBV transcriptional template [7]. Upon 3TC treat-
ment, most genes remained in a state reminiscent of
chronic HBV infection, whereby the expression patterns
of five genes downregulated in HBV-Met but none of the
upregulated genes became restituted (Figure 1B). Targeted
suppression of HBV by siRNA appeared more efficient,
leading to the restitution of eight genes (each four out of 20
up- or downregulated) in HBV-Met (Figure 1C), whereby
group 3 genes remained stable. However, since siRNA
treatment allows only short-term observation, we went on
to stably express antiviral RNA in HBV-Met. Earlier studies
encouraged us to utilize shRNA against HBV, since this
technique was applied before on HepG2.2.15 to study the
suppressive potency of anti-HBV-shRNA, and the cytotoxic
effects in this hepatoblastoma cell line reportedly appeared
negligible [30]. In fact, we observed remarkable suppressive
potency by means of HBsAg assessments in cell culture su-
pernatants after 3 and 8 months during the observation
period (Figure 1D). However, on the gene expression level,
we observed massive deregulation effects with congruently
deviating patterns using either an antiviral or a nonsense
shRNA. These almost identical patterns and the omitted
contribution of the shRNA-cassette-deficient vector on
gene expression patterns suggested that these off-target ef-
fects were due to the shRNA in a sequence independent
manner. In line with this, fatal off-target effects upon ec-
topic shRNA expression in mice livers were observed be-
fore and were attributed to the oversaturation of cellular
RNA interference pathways [31]. It seems plausible that
those observations and the reasons for off-target effects
reported here could be mechanistically connected. Natur-
ally, such pronounced off-target effects are intolerable for
functional HBV-knockdown studies and certainly for
future applications in chronic HBV therapies. To circum-
vent putative hepatocellular ‘friend or foe’ recognition, we
mimicked hsa-miRNA-30-like molecules, which were
compared to other miRNA-like constructs for their sup-
pressive potency in prior experiments. Strikingly, using
this miRNA-like construct expressed from the pEPI-U6-
miRNA episome, we observed no off-target effects and afar better recovery of MMH-D3-like expression patterns.
Specifically, eight out of ten genes upregulated in HBV-
Met versus MMH-D3 were also upregulated in HBV-Met
when compared with miRNA-treated HBV-Met, and five
out of ten genes downregulated in HBV-Met versus
MMH-D3 were also downregulated in HBV-Met versus
miRNA-treated HBV-Met. These findings provide evi-
dence for a functional connection between deregulation of
these genes and the presence of HBV. We also hypothe-
sized that the gene expression deregulation was a pheno-
typic consequence of epigenome plasticity modulated by
HBV. Consequently, we analyzed HBV-induced promoter
DNA methylation patterns in HBV-Met. To date, few
studies focusing on limited numbers of selected genes are
available for describing HBV-induced changes in the hep-
atocyte epigenome. Most of them were done in HCC bi-
opsies or cell lines representing end stages of malignant
transformation. Some data were available for CDKN2A,
GSTP1, CDKN1A and some other genes [32-35], whereby
these genes were reported to be downregulated by pro-
moter CpG-island hypermethylation in HCC. Similarly, one
study reported similar hypermethylation in the CDKN2A
promoter in preneoplastic lesions. This led the authors to
suggest that CDKN2A hypermethylation was an early event
in HCC development [36]. Importantly, our data does not
support this conclusion, as we could not detect DNA
methylation pattern differences at any of the sites examined
(Figure 3). Notably, we examined mouse homologous sites
for CDKN2A and GSTP1 that were mentioned in the cited
literature. Moreover, we could not see any sign for hyper-
methylation in CDKN2A, whose DNA methylation level ra-
ther resembled that of hypomethylated GAPDH. Both sites
examined in GSTP1 reached intermediate DNA methyla-
tion levels if compared with a hypermethylated site in
TSH2B. In contrast to all relevant studies cited utilizing
techniques indiscriminative for DNA methylation or hydro-
xymethylation, we used specific antibodies against either
5meC or 5hmeC for immunoprecipitation. Interestingly,
with respect to the hydroxymethylated control gene SF1,
we observed 5hmeC enrichment at the same site in
CDKN2A, which was hypomethylated. We discovered more
instances for sites, where 5meC levels were low or moder-
ately elevated, but at the same time 5hmeC was enriched
(sites in CDH13, CDKN1A, MCL1, CDKN2A, GSTP1). This
might explain some of the discrepancies above described,
since a lack of discriminative techniques for 5meC and
5hmeC in the previous studies might have led to biased
quantification of DNA methylation [17]. Further, the few
studies available mostly focused on already transformed he-
patocytes. Taking this into account, earlier results and our
own data might not be mutually exclusive, but rather repre-
sent different stages in the malignant transformation
process with DNA hypermethylation not being an initial
but instead a late event for HBV-induced gene repression
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for the observed differential gene regulation, it was reason-
able to study the turnover of specific histone PTMs at
selected gene promoters. Strikingly, we found that turnover
of histone acetylation of the histone variant H2A.Z or at
lysine 9 of H3 differed at all sites examined between
MMH-D3 and HBV-Met (Figure 4) with significant hypoa-
cetylation in HBV-Met. This would be in agreement with
the hypothesis that HDACs are involved in the HBV-
induced repression of selected genes [4].
In order to get insight into the mechanism of HBV-
induced histone hypoacetylation we tested several hypoth-
eses. We assumed that the detected hypoacetylation could
be due to one or more of the following mechanisms: 1) re-
duced HATactivity; 2) elevated HDAC activity; or 3) deso-
lation of epigenomic signatures, for example, through
reduced nucleosome occupancy. To test this, we measured
the activities of several enzymes involved in the regulation
of histone acetylation, that is, histone acetyltransferases
and histone deacetylases (class I/II HDACs and class III
HDACs/sirtuins). We observed that only the activity of
the NAD+-dependent sirtuins (silent mating type informa-
tion regulation 2 homolog/SIRT) differed between the
MMH-D3 and HBV-Met cells, suggesting that particularly
these class III HDACs could be involved in the HBV-
driven histone hypoacetylation, which appeared to be an
early pre-HCC event in hepatitis B. Our results indicate
slightly elevated mRNA levels for SIRT1, SIRT2, SIRT5
and SIRT7 in HBV-Met cells when compared to MMH-
D3, although the biological relevance of this observation
remains undisclosed. It seems likely - rather than deducing
differential histone acetylation levels from changes in the
expression of sirtuin genes - that the deregulation of sir-
tuins could occur on the protein level, which might lead to
changes in their chromatin recruitment or turnover, re-
spectively. It is interesting in this context that two very re-
cent studies report a physical association between SIRT1
with the HBV cccDNA and that SIRT1 is apparently tightly
involved in the upregulation of viral transcription [37,38]. It
may be carefully speculated that upregulation of SIRT1 by
HBV could lead to globally changed acetylation signatures
in the host cell epigenome. Moreover, we showed that glo-
bal histone hypoacetylation in HBV-Met cells correlated
with changes in the chromatin structure. In detail, HBV-
Met chromatin was significantly less sensitive to MNase,
suggesting a globally more condensed chromatin structure.
Interestingly, at all selected sites examined by ChIP-
qPCR, histone deacetylation in the HBV-Met cells could be
partly restituted via a nucleoside analog reverse transcript-
ase inhibitor or by anti-HBV miRNA-like molecules mim-
icking hsa-miRNA-30a, whereas ectopic expression of
antiviral shRNA seemed to provoke intolerable off-target
effects on the gene expression level. In the future, this has
to be taken into account with respect to the open problem,whether therapies lead to the restitution of regular chroma-
tin signatures, or whether hepatocytes persist in a deregu-
lated epigenetic ‘memory’ state of HBV infection and thus
still carrying the risk for later malignant transformation.
Conclusions
Taken together, our experiments demonstrated that an in-
creased activity of sirtuins, which might lead to global his-
tone hypoacetylation signatures, could contribute to the
HBV-induced pathomechanism in nontransformed hepa-
tocytes during hepatitis B. In contrast to studies in hepa-
toma cells, we could not find evidence for the importance
of DNA hypermethylation as an early event, the involve-
ment of HAT or class I/II HDACs on an epigenome-wide
level or a desolation of the nucleosome landscape in the
HBV-Met chromatin.
Our ChIP experiments, moreover, suggested that im-
paired HBV-replication by either 3TC or antiviral miRNA
expression, and to a lesser extent by shRNA, apparently
resulted in a restitution of H2A.Zac and H3K9ac signa-
tures at different grades and at all sites examined. These
results strongly suggested that the observed changes in
chromatin structure were mechanistically driven by HBV
or its transcription, respectively. The resulting patterns
were reminiscent of MMH-D3 with only single sites occa-
sionally remaining in an HBV-Met-like state. The best
recovery of MMH-D3-like gene expression without ob-
servable off-target effects was observed in HBV-Met
treated with miRNA-like molecules. We therefore con-
cluded that the observed effects on the chromatin signa-
ture in HBV expressing hepatocytes were indeed directly
induced by the presence/replicative activity of HBV.
Methods
Cells and specimens
MMH-D3 and HBV-Met cells were cultivated as de-
scribed elsewhere [7,8]. In some experiments, cells were
treated with 25 μM 3TC (Sigma Aldrich, St. Louis, MO,
USA). Pediatric human specimens were obtained from
patients who routinely underwent diagnostic needle as-
piration liver biopsy. Written informed consent for re-
search material was obtained from all legal guardians.
All work has been conducted according to the principles
expressed in the Declaration of Helsinki. Mice liver samples
of the 1.2.32 (Tg [HBV 1.3 genome] Chi32) lineage (HCC
negative and HCC positive) were kindly donated by Ulrike
Protzer, Institute of Virology, TU Munich, Germany.
Hepatitis B surface antigen measurements
Hepatitis B surface antigen (HBsAg) concentrations in cell
culture supernatants were quantified using the Elecsys
HBsAg II ELISA test (Roche Diagnostics, Rotkreuz, Risch,
Switzerland).
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Prior to gene expression analyses, RNA was isolated
from at least three biological replicates for each experi-
ment using Trizol reagent (Sigma Aldrich, St. Louis,
MO, USA) according to the manufacturer’s recommen-
dations. RNA integrity was checked using an Agilent
Bioanalyzer 2100 with the Agilent RNA 6000 Nano Kit
for microcapillary electrophoresis (Agilent Technologies,
Santa Clara, CA, USA). Using the RT2 First Strand
kit (Qiagen/SABiosciences, Hilden, Germany), cDNA
templates were synthesized from 1 μg RNA. Gene ex-
pression was analyzed from these cDNAs using RT2
Profiler PCR arrays (PAMM-133R; Qiagen/SABios-
ciences, Hilden, Germany), which contained validated
primers for 84 genes [see Additional file 1: Figure S4]
relevant for liver cancer development, 5 housekeeping
genes and quality control primers for estimation of re-
verse transcription efficiency and genomic DNA con-
tamination on a Corbett Rotor-Gene 6000 qPCR device
(Qiagen, Hilden, Germany). In some experiments, we
measured the accumulation of SIRT1-7 mRNA using
the primer pairs displayed in Table 2. The housekeep-
ing genes ACTB, GAPDH and RPL19 were used for
normalization. For relative comparative quantification
of gene expression fold changes we applied the ΔΔCt
method [39] using at least three housekeeping genes
for normalization.
RNA interference
For RNA interference we used annealed duplex siRNA oli-
gos and HiPerFect transfection reagent (Qiagen, Hilden,
Germany). Long-term suppression using shRNA/miRNA
was achieved using the pEPI vector system [9] with the
luciferase-S/MAR transcription unit under control of the
human hepatocyte-specific alpha 1-antitrypsin promoter
(A1AT). The shRNA/miRNA targeted against HBV was
expressed under control of the human U6 or H1 RNA
polymerase III promoters downstream of the S/MAR
cassette. Plasmids were transfected into HBV-Met usingTable 2 Primer pairs used for the detection of murine
SIRT1-7 mRNAs by quantitative real-time polymerase
chain reaction (qPCR)
Name Forward primer Reverse primer Amplicon
size
mmuSIRT1 Ggccgcggataggtccata acaatctgccacagcgtcat 136 bp
mmuSIRT2 Gtgcaggaggctcaggatt tgtagcgtgtcactccttcg 163 bp
mmuSIRT3 Cgctaaacttctcccgggtt cctgtaacactagtcctcgcc 156 bp
mmuSIRT4 Aacccgactgtttagccgtt ccgctcattcttattctgtctgg 190 bp
mmuSIRT5 Caccgacagattcaggtttca agtgccctgctttagcactc 155 bp
mmuSIRT6 Cacaaaacatgaccgccagg ctgcaccattgagatgcacg 191 bp
mmuSIRT7 Tctacaaccggtggcaggat cctcctaggatagggggagc 160 bpLipofectamine 2000 (Life Technologies, Carlsbad, CA,
USA), followed by G418 selection for 10 days. Sampling
was done at the time points indicated below.
Analyses of CpG signaling
DNA methylation/hydroxymethylation was assessed via
methylated DNA immunoprecipitation (MeDIP/hMeDIP)
as described previously [40]. Briefly, genomic DNA was
isolated by phenol:choroform:isoamylalcohol extraction,
sheared by ultrasonic treatment prior to pull-down of
5meC or 5hmeC containing fragments using antibodies
selective for either methylated or hydroxymethylated
DNA (Diagenode, Liège, Belgium). Relative enrichment
of precipitated sequences in MeDIP was assessed using
qPCR.
Western blots
For Western analyses, nuclear proteins were resuspended
in loading buffer, heated for 10 minutes at 95°C, and sepa-
rated by SDS-PAGE (12% gels). Proteins were then trans-
ferred in Towbin buffer onto a PVDF membrane and
probed with specific antibodies (Diagenode rabbit anti-
H2A.Zac or Diagenode rabbit anti-H3K9ac [Diagenode,
Liège, Belgium]). Secondary detection was performed
using HRP-conjugated pAbs and enhanced chemolumi-
nescence (ECL) substrate (Pierce/Thermo-Fisher, Rockford,
Illinois, USA).
Histone acetyltransferase/histone deacetylase activity
assays
For histone acetyltransferase (HAT)/histone deacety-
lase (HDAC) activity assays, cells were counted by flow
cytometry. HAT activity was assessed in MMH-D3 and
HBV-Met nuclear extracts corresponding to 10.000
cells using the Epigentek EpiQuick HAT activity assay
for ELISA (Epigentek, Farmingdale, NY, USA). Prior to
absorbance detection at OD 450, HAT activity within
those nuclear extracts was used to acetylate an immobi-
lized histone substrate in the presence of acetyl Co-A.
Then, acetylated substrates were recognized by means
of specific antibodies and quantified by colorimetry.
Histone deacetylase activities of either HDAC classes
I/II or class III (sirtuins) were measured by means of
luminescence reporter assays (Promega, Madison, WI,
USA) using 10.000 cells for the class I/II HDAC assay
(Promega HDAC Glo) or 20.000 cells for the sirtuin
assay (Promega Sirt Glo). Prior to this, both MMH-D3
and HBV-Met cells were diluted in serum-free medium
to a final volume of 100 μl per well. For HDAC and
sirtuin assays, diluted cells, developer reagent and
enzyme inhibitors were added and luminescence was
detected at discrete time points using a Promega GloMax
microplate reader (Promega, Madison, WI, USA).
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For Micrococcus nuclease assays, whole cell lysates were
layered onto a 1.2 M sucrose cushion (1.2 M sucrose in
60 mM, KCl 15 mM NaCl, 5 mM MgCl2, 0.1 mM ethyl-
ene glycol tetraacetic acid (EGTA), 15 mM Tris–HCl
(pH 7.5), 0.5 mM DTT, 0.1 mM phenylmethanesul-
fonylfluoride (PMSF), and 3.6 ng/mL aprotinin) and
centrifuged as described elsewhere [41]. Nuclei were
collected and homogenized in Micrococcus nuclease
(MNase) digestion buffer (0.32 M sucrose, 50 mM
Tris–HCl (pH 7.5), 4 mM MgCl2, 1 mM CaCl2, and
0.1 mM PMSF). MNase digest time courses of each 1 × 106
cells were performed for 0, 1, 2, 4, 8, 16 or 20 minutes with
0.15 U/μL MNase (Thermo Fisher Scientific, Waltham,
MA, USA). The reactions were stopped by directly
mixing 50 μL phenol:chloroform:isoamylalcohol with
each sample followed by DNA extraction. From the
aqueous phase DNA was precipitated with isopropanol,
resolved in water and DNA fragments were analyzed
on an Agilent Bioanalyzer 2100 using a DNA chip.
Chromatin immunoprecipitation
Chromatin isolation and chromatin immunoprecipitation
(ChIP) analyses were carried out as described [42]. Anti-
bodies used for ChIP were directed against H2A.Zac
(Diagenode, Liège, Belgium), H3K4me1 (Diagenode, Liège,
Belgium), H3K4me3 (Diagenode, Liège, Belgium), H3K9ac
(Active Motif, Carlsbad, CA, USA), H3K9me3 (Active
Motif, Carlsbad, CA, USA), H3K9me3S10ph (Diagenode,
Liège, Belgium) or H3K27me3 (Active Motif, Carlsbad,
CA, USA). Relative enrichment of precipitated sequences
in ChIP was assessed using qPCR.
Additional file
Additional file 1: Restitution of gene expression and histone
acetylation signatures altered by hepatitis B virus through antiviral
microRNA-like molecules in nontransformed murine hepatocytes.
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